Pirfenidone ameliorated AGE-induced EMT and attenuated peritoneal fibrosis in peritoneal mesothelial cells

Cerebrovascular and Neurological Disorders: Protective Role of NRF2

(2019) Farzane Sivandzade et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

ST2 blockade mitigates peritoneal fibrosis induced by TGF‐β and high glucose

(2019) Yong Chul Kim et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pirfenidone attenuates the profibrotic contractile phenotype of differentiated human dermal myofibroblasts

(2019) Adrienne R. Wells et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The efficacy of pirfenidone in a sheep model of pulmonary fibrosis

(2019) Sasika N. V. Dewage et al.   EXPERIMENTAL LUNG RESEARCH

Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice

(2019) Mostafa M. Salah et al.   LIFE SCIENCES

OUP accepted manuscript

(2018)   EUROPEAN HEART JOURNAL

RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis

(2018) Qinglian Wang et al.   Oncotarget

Pkcδ Activation is Involved in ROS-Mediated Mitochondrial Dysfunction and Apoptosis in Cardiomyocytes Exposed to Advanced Glycation End Products (Ages)

(2018) Yao-Chih Yang et al.   Aging and Disease

EMT Transition States during Tumor Progression and Metastasis

(2018) Ievgenia Pastushenko et al.   TRENDS IN CELL BIOLOGY

Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy

(2017) B N M K Khanum et al.   EYE

Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis

(2017) Chunmei Li et al.   Scientific Reports

Changes in the worldwide epidemiology of peritoneal dialysis

(2016) Philip Kam-Tao Li et al.   Nature Reviews Nephrology

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models

(2016) Wencheng Yu et al.   PHARMACEUTICAL BIOLOGY

Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis

(2016) Raffaele Strippoli et al.   Stem Cells International

Peritoneal Dialysis–Related Peritonitis: Towards Improving Evidence, Practices, and Outcomes

(2014) Yeoungjee Cho et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

(2014) Lucia Flores-Contreras et al.   BMC GASTROENTEROLOGY

Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy

(2013) Yan-Ming Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Diabetic Nephropathy and Extracellular Matrix

(2012) S. O. Kolset et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

The cytoprotective role of the Keap1–Nrf2 pathway

(2011) Liam Baird et al.   ARCHIVES OF TOXICOLOGY

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

(2010) Monique E Cho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The NRF2–heme oxygenase-1 system modulates cyclosporin A-induced epithelial–mesenchymal transition and renal fibrosis

(2010) Dong-ha Shin et al.   FREE RADICAL BIOLOGY AND MEDICINE

Epigenetic Changes Induced by Reactive Oxygen Species in Hepatocellular Carcinoma: Methylation of the E-cadherin Promoter

(2008) Seung-Oe Lim et al.   GASTROENTEROLOGY